Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Toronto Stock Exchange  >  Cardiome Pharma Corp    COM   CA14159U3010

SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

CARD PHARM : Cardiome to Hold Conference Call to Discuss First Quarter Results and Corporate Update

share with twitter share with LinkedIn share with facebook
share via e-mail
0
07/25/2011 | 11:56pm CEST

Vancouver, Canada, July 25th, 2011 ? Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) today announced it will hold a conference call to discuss Q1-2011 financial results and to provide a corporate update.

To access the conference call, please dial 416-340-2217 or 866-696-5910 and reference conference 6435784 . There will be a separate dial-in line for analysts on which we will respond to questions at the end of the call. The webcast can be accessed through Cardiome?s website at www.cardiome.com .

Webcast and telephone replays of the conference call will be available approximately two hours after the completion of the call through August 26th, 2011. Please dial 905-694-9451 or 800-408-3053 and enter code 7372760# to access the replay.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. is a product-focused drug development company dedicated to the advancement and commercialization of novel treatments for disorders of the heart and circulatory system. Cardiome is traded on the NASDAQ Global Market (CRME) and the Toronto Stock Exchange (COM). For more information, please visit our web site at www.cardiome.com.

For Further Information:  

Cardiome Investor Relations  (604) 676-6993 or Toll Free: 1-800-330-9928 Email: [email protected]

Forward-Looking Statement Disclaimer

Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact, including without limitation statements containing the words ?believe?, ?may?, ?plan?, ?will?, ?estimate?, ?continue?, ?anticipate?, ?intend?, ?expect? and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments expressed or implied by such forward-looking statements or information. Such factors include, among others, our stage of development, lack of product revenues, additional capital requirements, risk associated with the completion of clinical trials and obtaining regulatory approval to market our products, the ability to protect our intellectual property, dependence on collaborative partners and the prospects for negotiating additional corporate collaborations or licensing arrangements and their timing. Specifically, certain risks and uncertainties that could cause such actual events or results expressed or implied by such forward-looking statements and information to differ materially from any future events or results expressed or implied by such statements and information include, but are not limited to, the risks and uncertainties that: we may not be able to successfully develop and obtain regulatory approval for vernakalant (iv) or vernakalant (oral) in the treatment of atrial fibrillation or any other current or future products in our targeted indications; our future operating results are uncertain and likely to fluctuate; we may not be able to raise additional capital; we may not be successful in establishing additional corporate collaborations or licensing arrangements; we may not be able to establish marketing and sales capabilities and the costs of launching our products may be greater than anticipated; we rely on third parties for the continued supply and manufacture of vernakalant (iv) and vernakalant (oral) and we have no experience in commercial manufacturing; we may face unknown risks related to intellectual property matters; we face increased competition from pharmaceutical and biotechnology companies; and other factors as described in detail in our filings with the Securities and Exchange Commission available at www.sec.gov and the Canadian securities regulatory authorities at www.sedar.com. Given these risks and uncertainties, you are cautioned not to place undue reliance on such forward-looking statements and information, which are qualified in their entirety by this cautionary statement. All forward-looking statements and information made herein are based on our current expectations and we undertake no obligation to revise or update such forward-looking statements and information to reflect subsequent events or circumstances, except as required by law.

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CARDIOME PHARMA CORP
04/26 CARDIOME PHARMA CORP : Research Reports Initiated on Healthcare Stocks: Cardiome..
04/06 CARDIOME PHARMA : Partner SteadyMed Announces Successful Completion of TREVYENT®..
04/06 CARDIOME PHARMA : Partner SteadyMed Announces Successful Completion of Trevyent®..
04/03 CARDIOME PHARMA : Partner SteadyMed Receives Favourable Ruling In Its USPTO Inte..
04/03 CARDIOME PHARMA : Partner SteadyMed Receives Favourable Ruling in its USPTO Inte..
03/23 CARDIOME PHARMA : Reports Fourth Quarter And Full Year 2016 Financial Results
03/17 CARDIOME PHARMA : Receives notice of compliance from health canada for its brina..
03/16 CARDIOME PHARMA CORP : Research Reports Initiated on Healthcare Stocks Cardiome ..
03/14 CARDIOME PHARMA : IIROC Trade Resumption - COM
03/14 IIROC Trade Resumption - Cardiome Pharma Corp.
More news
Sector news : Biopharmaceuticals
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/26DJGLAXOSMITHKLINE : Glaxo's New Boss Emma Walmsley Seeks Sharper R&D Edge--Update
04/26DJGLAXOSMITHKLINE : Net Income Boosted by Strong Sales, Weak Pound
04/25DJSHIRE : Files 8K - Other Events
04/25DJSHIRE : Files 8K - Changes To Articles
More sector news : Biopharmaceuticals
News from SeekingAlpha
04/03 SteadyMed prevails in challenge to United Therapeutics' patents covering Remo..
03/14 Cardiome cleared to commercialize Brinavess in Canada; shares ahead 2%
03/07 Cardiome Pharma's (CRME) CEO Bill Hunter on Q4 2016 Results - Earnings Call T..
03/07 Cardiome Pharma misses by $0.06, beats on revenue
03/03 Cardiome launches antibiotic XYDALBA in France; shares ahead 3%
Advertisement
Financials ( CAD)
Sales 2017 42,5 M
EBIT 2017 -14,4 M
Net income 2017 -24,3 M
Debt 2017 -
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales 2017 3,28x
Capi. / Sales 2018 2,56x
Capitalization 139 M
More Financials
Chart CARDIOME PHARMA CORP
Duration : Period :
Cardiome Pharma Corp Technical Analysis Chart | COM | CA14159U3010 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 11,3  CAD
Spread / Average Target 160%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
William L. Hunter President, Chief Executive Officer & Director
William James O'Shea Chairman
Sheila M. Grant Chief Operating Officer
Jennifer Archibald Chief Financial Officer
Richard M. Glickman Lead Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CARDIOME PHARMA CORP13.38%103
BIOGEN INC9.78%61 954
CSL LIMITED28.06%44 240
ALEXION PHARMACEUTICAL..-1.47%27 142
GRIFOLS SA29.32%16 800
BIOMARIN PHARMACEUTICA..13.70%16 282
More Results